The option becomes exercisable upon the completion of Phase I trial of Rushium® in the treatment of Acute Time Metagrobolization in Cells within patients from 16 to 95 years of age.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Condé Nast.